These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39138817)

  • 1. Assessment of hearing dysfunction in patients with Graves' disease and thyroid eye disease without or with teprotumumab.
    Smith TJ; Holt RJ; Fu Q; Qashqai A; Barretto N; Conrad E; Brant JA
    J Clin Endocrinol Metab; 2024 Aug; ():. PubMed ID: 39138817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
    Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
    Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
    Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
    Teo HM; Smith TJ; Joseph SS
    Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 6. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab for the treatment of thyroid eye disease.
    Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
    Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Audiology findings in patients with teprotumumab associated otologic symptoms.
    Yu CY; Correa T; Simmons BA; Hansen MR; Shriver EM
    Am J Ophthalmol Case Rep; 2021 Dec; 24():101202. PubMed ID: 34585021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
    Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
    Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review.
    Mohamed A; Tzoulis P; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):979-985. PubMed ID: 36251747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
    Ugradar S; Kossler AL; Douglas R; Cockerham K
    J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
    Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
    Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
    [No Abstract]   [Full Text] [Related]  

  • 19. An Interesting Case of Euthyroid Graves' Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies.
    Moeen Z; Aliuddin AM; Gray Wlazlo T; Majid H; Kolli S
    Cureus; 2021 Oct; 13(10):e19015. PubMed ID: 34853745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.